Holen Sie sich die Stockscreener-App
6.01
0.17%
0.010
Handel nachbörslich:
6.00
-0.010
-0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.00
Offen:
$5.9101
24-Stunden-Volumen:
3.99M
Relative Volume:
0.87
Marktkapitalisierung:
$1.03B
Einnahmen:
$847.25M
Nettoeinkommen (Verlust:
$-284.86M
KGV:
-2.6245
EPS:
-2.29
Netto-Cashflow:
$-112.35M
1W Leistung:
-6.24%
1M Leistung:
-20.92%
6M Leistung:
-40.73%
1J Leistung:
+51.39%
1-Tages-Spanne:
$5.87
$6.265
1-Wochen-Bereich:
$5.81
$6.58
52-Wochen-Spanne:
$3.90
$23.86
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.01 | 1.03B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com
Novavax (NVAX) Shows Promising Vaccine Results Amid Market Stability - GuruFocus
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gaithersburg-Based Novavax’s COVID-19 Vaccine Shows Lower Side Effects Than Pfizer-BioNTech - The MoCo Show -
Lobbying Update: $50,000 of NOVAVAX INC. lobbying was just disclosed - Nasdaq
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax (NasdaqGS:NVAX) Study Shows Reduced Symptoms With New COVID-19 Vaccine Formula - Yahoo Finance
At ACIP hearing, CDC says it's 'scraping' to respond to measles outbreak; FDA comments on Novavax halt - Endpoints News
Novavax vaccine shows fewer side effects in study By Investing.com - Investing.com South Africa
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Novavax Inc (NVAX) Stock Price, Trades & News - GuruFocus
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
US CDC advisers begin review of vaccine guidelines after months-long delay - marketscreener.com
Novavax vaccine shows fewer side effects in study - Investing.com Australia
Novavax Says COVID-19 Vaccine Induces Fewer Symptoms Compared With Pfizer's Vaccine - marketscreener.com
Novavax (NVAX) COVID-19 Vaccine Shows Lower Reactogenicity in SH - GuruFocus
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower - GuruFocus
Shield-Utah Study Shows Novavax's Covid-19 Vaccine Induces Lower Reactogenicity Symptoms Compared To Mrna - marketscreener.com
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab - MSN
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA - The Herald Journal
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax (NVAX) Stock Plunges Amid Approval Delay - GuruFocus
Shares plunge after RFK Jr questions Novavax approach - The Pharma Letter
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling - MSN
Novavax (NVAX) Shares Plummet Amid Vaccine Effectiveness Concerns - GuruFocus
Novavax slides after RFK Jr. casts doubts about COVID vaccine - Yahoo Finance
Novavax (NVAX) Awaits FDA Decision Amid Vaccine Approval Delay | - GuruFocus
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer - Seeking Alpha
Novavax (NVAX) Faces Setback Amid COVID Vaccine Approval Delay - GuruFocus
Kennedy’s Comments On Novavax Delay Scientifically, Legally Inaccurate, Experts Say - insights.citeline.com
Update on Status of Novavax's COVID-19 Vaccine BLA - marketscreener.com
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy - Reuters
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot’s efficacy - KFGO
Nike, Disney, Novavax: Trending Tickers - Yahoo Finance
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work - MSN
Novavax (NVAX) Stock Target Lowered Amidst Vaccine Approval Conc - GuruFocus
Novavax (NVAX) Shares Plunge After RFK Jr. Questions Its Covid Vaccine Efficacy - Bloomberg.com
Sector Update: Health Care Stocks Drop Thursday Afternoon - TradingView
BofA cuts Novavax stock price target to $10 from $12 - Investing.com
Novavax & RFK Jr., Costco sales, Lovesac earnings: Market Minute - Yahoo Finance
Novavax tumbles as Kennedy raises questions over COVID vaccine - TradingView
Novavax Shares Fall After RFK Jr. Questions Covid-19 Vaccine - marketscreener.com
Novavax (NVAX) Faces Stock Drop Amid FDA Vaccine Approval Delay - GuruFocus
Novavax Shares Plunge After RFK Jr. Questions Its Covid Vaccine - Bloomberg
Vaccine Makers Fall After RFK Jr. Says Some Shots Don’t Work (1) - Bloomberg Law News
Novavax in selloff after RFK Jr.’s comments on COVID vaccine - MSN
Japan approves Moderna COVID vaccine as booster, Novavax files for 1st approval - tuoitrenews.vn
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Yahoo Finance
Novavax (NasdaqGS:NVAX) Announces Leadership Change With New Board Appointments - Yahoo Finance
Novavax Inc. stock rises Wednesday, still underperforms market - MarketWatch
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):